Catalyst Pharmaceuticals (CPRX) Net Cash Flow (2010 - 2026)

Catalyst Pharmaceuticals has reported Net Cash Flow for 17 years, with the latest figure at $46.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 26.01% year-over-year to $46.7 million; the trailing twelve-month figure through Mar 2026 stood at $175.2 million (down 35.17% YoY), and the FY2025 full-year result was $191.6 million, down 49.56% from the prior year.
• Net Cash Flow for Q1 2026 stood at $46.7 million, up from $19.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $172.8 million in Q1 2024, with the low at -$150.1 million in Q1 2023.
• Historically, Net Cash Flow has averaged $33.8 million across 5 years, with a median of $42.3 million in 2022.
• Annual changes were most pronounced in 2023 — Net Cash Flow tumbled 2267.58% — and 2024, when it surged 351.38%.
• Catalyst Pharmaceuticals' Net Cash Flow stood at $42.3 million in 2022, then sank by 60.63% to $16.7 million in 2023, then surged by 351.38% to $75.2 million in 2024, then slumped by 74.37% to $19.3 million in 2025, then surged by 142.17% to $46.7 million in 2026.
• The last three Net Cash Flow figures came in at $46.7 million (Q1 2026), $19.3 million (Q4 2025), and $37.1 million (Q3 2025), per Business Quant data.